Der Nephrologe

, Volume 7, Issue 2, pp 160–162

Orale Antikoagulation mit Dabigatran bei eingeschränkter Nierenfunktion

Nephro molekular
  • 113 Downloads

Oral anticoagulation with dabigatran for limited renal function

Literatur

  1. 1.
    Anand S, Yusuf S, Xie C et al; (2007) Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357(3):217–227PubMedCrossRefGoogle Scholar
  2. 2.
    Mendoza V, Scharf ML (2011) Evaluation and management of chronic pulmonary thromboembolic disease. Hosp Pract (Minneap) 39(3):50–61Google Scholar
  3. 3.
    Potpara TS, Lip GY (2011) New anticoagulation drugs for atrial fibrillation. Clin Pharmacol Ther 90(4):502–506PubMedCrossRefGoogle Scholar
  4. 4.
    Voller H, Alban S, Westermann D (2010) New oral anticoagulants: better than vitamin K antagonists? Internist (Berl) 51(12):1571–1581Google Scholar
  5. 5.
    Hirsh J, Dalen JE, Deykin D et al (1992) Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 102(4 Suppl):312S–326SPubMedGoogle Scholar
  6. 6.
    McKellar SH, Abel S, Camp CL et al (2011) Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg 141(6):1410–1416PubMedCrossRefGoogle Scholar
  7. 7.
    Ganetsky M, Babu KM, Salhanick SD et al (2011) Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol 7(4):281–287PubMedCrossRefGoogle Scholar
  8. 8.
    Zeidan A, Faltas B, Streiff M (2011) Dabigatran etexilate: what do hospitalists need to know? J Hosp Med [Epub ahead of print]Google Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Abteilung Nephrologie und RheumatologieUniversitätsklinikum GöttingenGöttingenDeutschland

Personalised recommendations